Cemalettin Yılmaz, Ahmet Karaduman, Muhammet Mücahit Tiryaki, Büşra Güvendi Şengör, Tuba Unkun, Barkın Kültürsay, Regayip Zehir
{"title":"那不勒斯预后评分对隐静脉支架植入术后无血流现象的预测价值。","authors":"Cemalettin Yılmaz, Ahmet Karaduman, Muhammet Mücahit Tiryaki, Büşra Güvendi Şengör, Tuba Unkun, Barkın Kültürsay, Regayip Zehir","doi":"10.1080/17520363.2024.2443383","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>No-reflow is a critical adverse event associated with percutaneous coronary intervention (PCI), particularly during saphenous vein graft (SVG) procedures. The Naples Prognostic Score (NPS) reflects inflammatory status, but its relationship with no-reflow remains unclear. Therefore, we aimed to evaluate the relationship between NPS and no-reflow occurrence following SVG PCI.</p><p><strong>Methods: </strong>We retrospectively analyzed 286 patients who underwent SVG PCI from January 2020 to January 2024, with a median age of 65 years and 85.7% male. Participants were categorized into low NPS (0-2, 48.6%) and high NPS (3-4, 51.4%) groups. Two nested models were developed by adding NPS (continuous and categorical, respectively) to the base model.</p><p><strong>Results: </strong>Higher no-reflow rates were noted in the high-NPS group (48.5% vs. 9.5%, <i>p</i> < 0.05). Multivariable regression revealed that a higher NPS significantly increased no-reflow risk, with odds ratios of 5.966 (95% CI: 3.066-11.611) for continuous NPS and 10.110 (95% CI: 3.194-32.002) for categorical NPS. Adding NPS to the base model significantly improved predictive performance (likelihood-ratio test <i>p</i> < 0.001). Model 1 demonstrated the best performance (X<sup>2</sup> : 84.857, R<sup>2</sup> : 0.468) and discriminative ability (AUC: 0.888).</p><p><strong>Conclusion: </strong>Our findings suggest that NPS is a strong predictor of no-reflow following SVG PCI.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"13-22"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731040/pdf/","citationCount":"0","resultStr":"{\"title\":\"Predictive value of the Naples prognostic score for no-reflow phenomenon after saphenous vein graft stenting.\",\"authors\":\"Cemalettin Yılmaz, Ahmet Karaduman, Muhammet Mücahit Tiryaki, Büşra Güvendi Şengör, Tuba Unkun, Barkın Kültürsay, Regayip Zehir\",\"doi\":\"10.1080/17520363.2024.2443383\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>No-reflow is a critical adverse event associated with percutaneous coronary intervention (PCI), particularly during saphenous vein graft (SVG) procedures. The Naples Prognostic Score (NPS) reflects inflammatory status, but its relationship with no-reflow remains unclear. Therefore, we aimed to evaluate the relationship between NPS and no-reflow occurrence following SVG PCI.</p><p><strong>Methods: </strong>We retrospectively analyzed 286 patients who underwent SVG PCI from January 2020 to January 2024, with a median age of 65 years and 85.7% male. Participants were categorized into low NPS (0-2, 48.6%) and high NPS (3-4, 51.4%) groups. Two nested models were developed by adding NPS (continuous and categorical, respectively) to the base model.</p><p><strong>Results: </strong>Higher no-reflow rates were noted in the high-NPS group (48.5% vs. 9.5%, <i>p</i> < 0.05). Multivariable regression revealed that a higher NPS significantly increased no-reflow risk, with odds ratios of 5.966 (95% CI: 3.066-11.611) for continuous NPS and 10.110 (95% CI: 3.194-32.002) for categorical NPS. Adding NPS to the base model significantly improved predictive performance (likelihood-ratio test <i>p</i> < 0.001). Model 1 demonstrated the best performance (X<sup>2</sup> : 84.857, R<sup>2</sup> : 0.468) and discriminative ability (AUC: 0.888).</p><p><strong>Conclusion: </strong>Our findings suggest that NPS is a strong predictor of no-reflow following SVG PCI.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"13-22\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731040/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2024.2443383\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2443383","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：无血流循环是经皮冠状动脉介入治疗（PCI）的关键不良事件，特别是在隐静脉移植（SVG）手术中。那不勒斯预后评分（NPS）反映炎症状态，但其与无血流倒流的关系尚不清楚。因此，我们旨在评估SVG PCI术后NPS与无回流发生之间的关系。方法：回顾性分析2020年1月至2024年1月行SVG PCI手术的286例患者，中位年龄65岁，男性85.7%。参与者分为低NPS组（0-2,48.6%）和高NPS组（3-4,51.4%）。在基础模型上分别加入连续和分类NPS，建立了两个嵌套模型。结果：高nps组无血流再流率（48.5% vs. 9.5%, p p 2: 84.857, R2: 0.468）和判别能力（AUC: 0.888）较高。结论：我们的研究结果表明，NPS是SVG PCI术后无血流循环的一个强有力的预测指标。
Predictive value of the Naples prognostic score for no-reflow phenomenon after saphenous vein graft stenting.
Background: No-reflow is a critical adverse event associated with percutaneous coronary intervention (PCI), particularly during saphenous vein graft (SVG) procedures. The Naples Prognostic Score (NPS) reflects inflammatory status, but its relationship with no-reflow remains unclear. Therefore, we aimed to evaluate the relationship between NPS and no-reflow occurrence following SVG PCI.
Methods: We retrospectively analyzed 286 patients who underwent SVG PCI from January 2020 to January 2024, with a median age of 65 years and 85.7% male. Participants were categorized into low NPS (0-2, 48.6%) and high NPS (3-4, 51.4%) groups. Two nested models were developed by adding NPS (continuous and categorical, respectively) to the base model.
Results: Higher no-reflow rates were noted in the high-NPS group (48.5% vs. 9.5%, p < 0.05). Multivariable regression revealed that a higher NPS significantly increased no-reflow risk, with odds ratios of 5.966 (95% CI: 3.066-11.611) for continuous NPS and 10.110 (95% CI: 3.194-32.002) for categorical NPS. Adding NPS to the base model significantly improved predictive performance (likelihood-ratio test p < 0.001). Model 1 demonstrated the best performance (X2 : 84.857, R2 : 0.468) and discriminative ability (AUC: 0.888).
Conclusion: Our findings suggest that NPS is a strong predictor of no-reflow following SVG PCI.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
